Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × nintedanib × Tumor-Agnostic × Clear all

Phase

Phase 1 5 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 8 Gastrointestinal 7 Gynecologic 6 Genitourinary 4 Sarcoma 2 Other solid neoplasm 2 Head & Neck 2 CNS 2 Breast 2 Tumor-Agnostic 1 Other hematologic neoplasm 1

Conditions

Neoplasm Metastasis 1

Interventions

Paclitaxel 23 Gemcitabine 22 pembrolizumab 21 Carboplatin 21 Radiotherapy 14 Oxaliplatin 14 Cisplatin 14 Bevacizumab 14 Nivolumab 13 Erlotinib Hydrochloride 13 Fluorouracil 12 Capecitabine 12 Trastuzumab 11 Magnetic Resonance Spectroscopy 10 Leucovorin 10 Docetaxel 10 atezolizumab 9 Irinotecan 9 Everolimus 9 Vemurafenib 8 Ipilimumab 8 Cyclophosphamide 8 130-nm albumin-bound paclitaxel 8 Specimen Handling 7 Radiosurgery 7 Albumin-Bound Paclitaxel 7 Afatinib 7 lenvatinib 6 durvalumab 6 cabozantinib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02856867 2017-05-09

MEGAN

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡